<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H2CF32FB7C4B747398A96AEF0945B6233" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4287 IH: Independent Innovator and Repurposing Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-03-24</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>113th CONGRESS</congress>
<session>2d Session</session>
<legis-num>H. R. 4287</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20140324">March 24, 2014</action-date> 
<action-desc><sponsor name-id="C001091">Mr. Castro of Texas</sponsor> (for himself and <cosponsor name-id="F000445">Mr. Forbes</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HJU00">Committee on the Judiciary</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To advance the public health by encouraging independent innovators to pursue drug repurposing research and develop new treatments and cures by providing appropriate intellectual property protections for those innovations, and for other purposes.</official-title> 
</form> 
<legis-body id="HA07DDBB6DB19407B8BFE3CFB0A264940" style="OLC"> 
<section id="H6EFE728BB72D483AA11A748BA87654C9" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Independent Innovator and Repurposing Act</short-title></quote>.</text></section>
<section id="H2376DD4B785F44FEA84596FF78D84618"><enum>2.</enum><header>Extension of patent term for method of using biological product</header>
<subsection display-inline="no-display-inline" id="H7A8C4F49692348E8B96CAABFD43ACEC7"><enum>(a)</enum><header>Extension for regulatory delay</header><text display-inline="yes-display-inline">The term of a patent claiming a method of using a biological product shall be extended for 5 years from the original expiration date of the patent, which shall include any patent term adjustment granted under <external-xref legal-doc="usc" parsable-cite="usc/35/154">section 154(b)</external-xref> of title 35, United States Code, if—</text>
<paragraph id="HCB7F67B30DD241D6B5786DFBD72078FA"><enum>(1)</enum><text display-inline="yes-display-inline">an application for an extension is submitted by the owner of record of the patent or its agent in accordance with the requirements of subsection (b); and</text></paragraph>
<paragraph id="HD15159BC987B4966A73506C976B1821D"><enum>(2)</enum><text>the term of the patent—</text>
<subparagraph id="HF04AFC0DF5D748078E44591CD8F69EC6"><enum>(A)</enum><text>has not expired before the application is so submitted; and</text></subparagraph>
<subparagraph id="H4D8959C1CE324767B111777F3583E3BE"><enum>(B)</enum><text>has not been extended under subsection (c) of this section or <external-xref legal-doc="usc" parsable-cite="usc/35/156">section 156</external-xref> of title 35, United States Code.</text></subparagraph></paragraph></subsection>
<subsection id="H1BBD9708957147F79BB2F50731BAE490"><enum>(b)</enum><header>Application for extension</header><text display-inline="yes-display-inline">To obtain an extension of the term of a patent under this section, the owner of record of the patent or its agent shall submit an application to the Director. The application shall contain—</text>
<paragraph id="H60F2004B90F8450A9D1A62DED56CE0B3"><enum>(1)</enum><text display-inline="yes-display-inline">the identity of the biological product;</text></paragraph>
<paragraph id="HAF89A1548C9E4E31BD4FDECD9567C580"><enum>(2)</enum><text>the identity of the patent for which an extension is being sought and the identity of each claim of such patent that claims the method of using the biological product;</text></paragraph>
<paragraph commented="no" id="H12AE191FF75C4286AC7B5C163CC7A173"><enum>(3)</enum><text>information demonstrating to the Director that—</text>
<subparagraph commented="no" id="HDED1BA0C2F7349E08C61CA09F86A0FE4"><enum>(A)</enum><text display-inline="yes-display-inline">the patent was issued to an independent innovator;</text></subparagraph>
<subparagraph commented="no" id="H6F24179B20DD43F8A8A14D6B016CF4F2"><enum>(B)</enum><text>the owner of record is—</text>
<clause commented="no" id="HBE0740B8A57E442197F7675833EE3EE9"><enum>(i)</enum><text>the independent innovator; or</text></clause>
<clause commented="no" id="HD3B3145C960048D88F395910860EC352"><enum>(ii)</enum><text>a qualified small business in which the independent innovator has an ownership interest;</text></clause></subparagraph>
<subparagraph commented="no" id="HD80B51725B5B412288D00C5256F361EA"><enum>(C)</enum><text>an application under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>) for commercial marketing of the biological product for a method of use claimed in the patent has been filed; and</text></subparagraph>
<subparagraph commented="no" id="HE3C655C5405447FB9900FE8B05C16E14"><enum>(D)</enum><text display-inline="yes-display-inline">a period of not less than 10 years elapsed between the original date of submission of an application for an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) for investigating such method of use and the date on which the Food and Drug Administration approved the application described in subparagraph (C); and</text></subparagraph></paragraph>
<paragraph id="HC7E6FC2929DD4671A6436B3A9300F11F"><enum>(4)</enum><text display-inline="yes-display-inline">a brief description of the activities undertaken by the owner of record of the patent, or the agent of such owner, during such period with respect to the biological product and the significant dates applicable to such activities to the extent such information is possessed by such owner.</text></paragraph></subsection>
<subsection commented="no" id="H019DE6F3F1DB44099D97CFDED35EF6DD"><enum>(c)</enum><header>Determination of extension</header>
<paragraph commented="no" id="HA65F34B10B144F18B79680836A70D755"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">A determination that a patent is eligible for extension shall be made by the Director solely on the basis of the representations contained in the application for the extension. If the Director determines that a patent is eligible for extension under subsection (a) and that the requirements of subsection (b) have been complied with, the Director shall issue to the applicant for the extension of the term of the patent a certificate of extension, under seal, for 5 years. Such certificate shall be recorded in the official file of the patent and shall be considered as part of the original patent.</text></paragraph>
<paragraph commented="no" id="H02D9AF7C378D45B19DD16520FD7C3B26"><enum>(2)</enum><header>Interim extension</header><text display-inline="yes-display-inline">If the term of a patent for which an application has been submitted under subsection (b) would expire before a certificate of extension is issued or denied under paragraph (1) respecting the application, the Director shall extend, until such determination is made, the term of the patent for periods of up to one year if the Director determines that the patent is eligible for extension.</text></paragraph></subsection>
<subsection id="H230BDFE730744789941FA8E14DA2F92F"><enum>(d)</enum><header>Definitions</header><text>In this section:</text>
<paragraph id="H74C7FAD6E6B04696A31252106714A123"><enum>(1)</enum><header>Biological product</header><text>The term <term>biological product</term> has the meaning given to such term in section 351(i)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)(1)</external-xref>).</text></paragraph>
<paragraph id="HA78230A5795B41478DFA560A0EF047B9"><enum>(2)</enum><header>Director</header><text display-inline="yes-display-inline">The term <term>Director</term> means the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.</text></paragraph>
<paragraph id="H069E2E012D5646F5BB1888566DD3FD5B"><enum>(3)</enum><header>Independent innovator</header>
<subparagraph id="HB931EBC5EE2343A7B152EFBA72AE5915"><enum>(A)</enum><text>The term <term>independent innovator</term> means any person or entity that—</text>
<clause id="H38B333F4507B41E68209BA7EB6977C97"><enum>(i)</enum><text>obtains a method of use patent for a biological product; and</text></clause>
<clause id="HC05F82702B844CBD8C3EDA6C2B668ED6"><enum>(ii)</enum><text>is not, at the time of invention or patent filing, affiliated with the holder of a marketing application approved under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>) for the commercial marketing of such biological product.</text></clause></subparagraph>
<subparagraph id="HEF4AAAC414C846759D9C7F7C14F69F58"><enum>(B)</enum><text>For purposes of subparagraph (A) and paragraph (4), the term <term>affiliated</term> refers to any relationship of employment, control, or common ownership, whether direct or indirect, including through one or more intermediaries.</text></subparagraph></paragraph>
<paragraph id="H6C06EC5C75B447FBAF51C806CFD28E4E"><enum>(4)</enum><header>Qualified small business</header><text>The term <term>qualified small business</term> means any entity with fewer than 500 employees, including employees of affiliates, and which is not affiliated with the holder of the marketing application approved under section 351(a) of the Public Health Service Act (42 U.S.C. sec. 262(a)) for the commercial marketing of such biological product.</text></paragraph></subsection>
<subsection commented="no" id="H0D65B88BB05A4F738CD48ED559C68E5A"><enum>(e)</enum><header>Effective date</header><text display-inline="yes-display-inline">This section shall take effect on the date of the enactment of this Act and shall apply to any unexpired patent issued before, on, or after that effective date.</text></subsection></section> 
</legis-body> 
</bill> 


